Next Phase Newsletter

A venture capital firm with China headquarters and additional USA office is investing from its US$200 million fund with a focus on high-tech enterprises in China and Western countries. The firmseeks to invest in innovative enterprises in sectors including: biomedicine, medical devices, healthcare and bio-tech. Typical equity investments range from $1-6 million in Angel, Series A and B rounds. The firm is looking for opportunities in China, the US and Canada.

Within healthcare, the firm considers biomedicine, medical devices, and healthcare IT. The firm is most interested in personalized medicine products with an angle to the China market. Within healthcare IT, the firm prefers home-care, consumer, or physician-patient interface products. The firm considers products from Angel Round to Series B.

The firm is looking for competent management teams. The firm may request distribution rights on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A healthcare-focused venture investment fund with a team who are all trained in biomedical fields, with healthcare industry experience and years of successful investment or entrepreneurship experience in China, has past investment portfolio companies cover areas such as drug, device, diagnostics, healthcare IT and medical services. These investments were over $10MM and were made in venture rounds from Series A-C. The firm currently manages both RMB and US Dollar funds, investing in early and growth-stage companies in China and overseas. The firm believes in the huge industry growth and significant investment opportunities in China healthcare space for the next 10 to 20 years.

The firm has invested in therapeutics in a wide range of indications, including cancer, infectious diseases and autoimmune disorders. These investments covered a wide range of modalities including small molecules, antibodies and gene therapies. The firm additionally invested in medical device and imaging technologies, such as ultrasound and cardiovascular devices. Therapeutic investments were made during pre-clinical trials, while device investments were made pre-market. The firm invested in bioinformatics, research tools and animal medicine as well. The firm has invested in companies in the US, China and Western Europe.

The firm has no specific management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based venture capital firm with a new second fund closed in early 2020, invests in pre-seed through Series A rounds in exchange for equity. Typical allocations average in the $500k to $1.5M range. The main areas of interest for the firm are data-driven healthcare/biotech, enterprise software, and deep tech. The firm tends to focus on companies headquartered in North America.

The firm invests in software and hardware with proprietary algorithmic and design principles. For example, big data, AI/ML, robotics, and autonomous vehicles are of interest. Within data-driven health/biotech, the firm focuses on core technology innovations in computational health, synthetic biology, and digital health. Their portfolio includes companies involved in deep learning for medical imaging, genomics platforms and tools, in silico therapeutics discovery, large scale custom DNA synthesis, and a digital health platform consisting of software and integrated wearable hardware.

The firm seeks to work with management teams that have prior entrepreneurial experience or domain-specific technical or medical experience in the market they are targeting. They typically have regular check-ins with portfolio companies and can take on board seats.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm based in Western Europe currently manages three funds, the newest of which closed in 2020 and focuses on investments in Europe-based therapeutics and medical innovation. The firm invests in Europe and North America, and typically allocates €5 to €12 million equity to each portfolio company, generally over several tranches.

The firm invests in therapeutics. The firm is agnostic regarding technologies and indication areas, and typically invests early but is open to companies with assets ranging from preclinical development through Phase II.

The firm prefers to invest in companies that can present an exit opportunity in 3-5 years, usually through a pharmaceutical industry partnership.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private wealth investment vehicle based in Western Europe is looking to invest in therapeutics companies as well as companies developing digital therapeutics or therapeutic-enabling technologies. The firm is primarily interested in early stage, pre-clinical breakthrough technologies and, especially for digital-based companies, capital efficient business models. While the firm has invested primarily within Western Europe up until now, The firm is willing to consider companies in other geographies if they find the technology compelling. For a first investment, the firm invests, on average, 2M, but can invest smaller or larger amounts, depending on the company and its needs.

The firm is looking for companies in the broader therapeutics space. The firm is interested not only in more traditional therapeutics technologies, but also in digital therapeutics and digital therapeutic-enabling technologies, drug development platforms, including digital and genomics-based drug development technologies, and in cell and gene therapy manufacturing technologies. The firm has historically invested primarily in technologies relating to oncology, but will consider any indication.

The firm takes an active role with the companies in which they invest. The firm frequently leads rounds, and supports and mentors the early stage companies, often either taking a board seat themselves or finding an expert to serve on the board.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investor and developer of medical technologies headquartered in Asia with a subsidiary located in USA looks for new in-licensing or investment opportunities in cutting-edge medical device innovations from North America, Asia, and Europe, with no set cap on investment size.
With vertical integration of experienced medical professionals, talented engineers, and international infrastructure, the firm is dedicated to developing high value and high impact medical devices.

Focusing on minimally invasive surgical devices and healthcare information technologies, the firm invests in companies at any stage of development, from ideation, early product design, prototyping, preclinical testing, clinical trials to commercialization. The firm prefers disease states with sizable patient population, including but not limited to cardiovascular or peripheral vascular disease, orthopedics, neurosurgery, obesity, gastroenterology, hematology, nephrology, gynecology, urology, and plastic surgery.

The firm is looking for collaborations with competent entrepreneurs, physicians, companies and investors and willing to lead and co-invest in med-tech companies to develop novel solutions.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private equity firm founded in the USA invests in companies with high growth potential. The firm also considers in-licensing of technologies and strategic acquisitions. For equity investments, the firm prefers that companies are located in the Eastern US and Midwest, but for acquisitions and in-licensing, the firm will consider companies located around the globe. The firm also has an early-stage focused fund through which the firm makes angel investments into high potential, early-stage companies. With this fund, the firm typically invests up to $250K in preferred equity.

The firm primarily focuses on the following sectors: Diagnostics (including digital), Pharma Services/Outsourcing, Digital Health, and Medical Devices. The firm has a strong preference for companies working with platform technologies. For equity investments, the firm looks for companies that have reached commercialization. With regards to their early-stage fund, the firm primarily seeks companies in healthcare services and SaaS outsourcing businesses.

The firm is looking for experienced management teams with domain expertise and leadership skills that are capable of taking the company to the next value inflection point or additional capital raise. The firm is interested in company that are profitable or near breakeven and have demonstrated substantial opportunity for growth.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.